Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Holdings Boosted by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board lifted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 13,616.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 82,300 shares of the company's stock after acquiring an additional 81,700 shares during the period. Canada Pension Plan Investment Board owned 0.22% of Tarsus Pharmaceuticals worth $4,557,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of TARS. Summit Investment Advisors Inc. lifted its position in Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after acquiring an additional 244 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth $25,000. Bank of New York Mellon Corp grew its stake in shares of Tarsus Pharmaceuticals by 0.5% during the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after purchasing an additional 498 shares during the period. Swiss National Bank grew its stake in Tarsus Pharmaceuticals by 1.2% in the fourth quarter. Swiss National Bank now owns 52,333 shares of the company's stock valued at $2,898,000 after acquiring an additional 600 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in Tarsus Pharmaceuticals by 10.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock valued at $449,000 after acquiring an additional 789 shares during the period. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:TARS traded down $0.28 during trading hours on Monday, hitting $49.72. The company's stock had a trading volume of 685,350 shares, compared to its average volume of 689,959. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -13.05 and a beta of 0.94. The firm's fifty day moving average price is $47.60 and its 200 day moving average price is $48.53.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. As a group, research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 2,315 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the sale, the insider now owns 50,751 shares in the company, valued at approximately $2,349,263.79. The trade was a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Bryan Wahl sold 3,084 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $154,539.24. Following the completion of the transaction, the general counsel now directly owns 51,712 shares in the company, valued at approximately $2,591,288.32. The trade was a 5.63 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,542 shares of company stock worth $1,581,173. Insiders own 8.25% of the company's stock.

Wall Street Analysts Forecast Growth

TARS has been the topic of a number of recent analyst reports. HC Wainwright restated a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Barclays lowered their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Jefferies Financial Group lifted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Guggenheim reaffirmed a "buy" rating and issued a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Finally, Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.